75 related articles for article (PubMed ID: 21864040)
1. Rituximab plus 70% cyclophosphamide, doxorubicin, vincristine and prednisone for Japanese patients with diffuse large B-cell lymphoma aged 70 years and older.
Meguro A; Ozaki K; Sato K; Oh I; Fujiwara S; Hosonuma R; Sasazaki M; Kikuchi Y; Hirata Y; Yamamoto C; Uesawa M; Kobayashi H; Matsu H; Okabe H; Uehara E; Nishikawa A; Tatara R; Hatano K; Yamamoto C; Matsuyama T; Toshima M; Ueda M; Ohmine K; Suzuki T; Mori M; Nagai T; Muroi K; Ozawa K
Leuk Lymphoma; 2012 Jan; 53(1):43-9. PubMed ID: 21864040
[TBL] [Abstract][Full Text] [Related]
2. Outcome of elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: results from the UK NCRI R-CHOP14v21 trial with combined analysis of molecular characteristics with the DSHNHL RICOVER-60 trial.
Kühnl A; Cunningham D; Counsell N; Hawkes EA; Qian W; Smith P; Chadwick N; Lawrie A; Mouncey P; Jack A; Pocock C; Ardeshna KM; Radford J; McMillan A; Davies J; Turner D; Kruger A; Johnson PW; Gambell J; Rosenwald A; Ott G; Horn H; Ziepert M; Pfreundschuh M; Linch D
Ann Oncol; 2017 Jul; 28(7):1540-1546. PubMed ID: 28398499
[TBL] [Abstract][Full Text] [Related]
3. A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma.
Morschhauser F; Feugier P; Flinn IW; Gasiorowski R; Greil R; Illés Á; Johnson NA; Larouche JF; Lugtenburg PJ; Patti C; Salles GA; Trněný M; de Vos S; Mir F; Samineni D; Kim SY; Jiang Y; Punnoose E; Sinha A; Clark E; Spielewoy N; Humphrey K; Bazeos A; Zelenetz AD
Blood; 2021 Feb; 137(5):600-609. PubMed ID: 33538797
[TBL] [Abstract][Full Text] [Related]
4. Randomized phase II study of concurrent and sequential combinations of rituximab plus CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) chemotherapy in untreated indolent B-cell non-Hodgkin lymphoma: 7-year follow-up results.
Tobinai K; Ogura M; Itoh K; Kinoshita T; Hotta T; Watanabe T; Morishima Y; Igarashi T; Terauchi T; Ohashi Y;
Cancer Sci; 2010 Dec; 101(12):2579-85. PubMed ID: 20942866
[TBL] [Abstract][Full Text] [Related]
5. R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-14. A population-based investigation from the Danish Lymphoma Group.
Gang AO; Strøm C; Pedersen M; d'Amore F; Pedersen LM; Bukh A; Pedersen BB; Moeller MB; Mortensen LS; Gadeberg OV; Ingeberg S; Mourits-Andersen T; Pulczynski S; Brown PDN
Ann Oncol; 2012 Jan; 23(1):147-153. PubMed ID: 21460380
[TBL] [Abstract][Full Text] [Related]
6. Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy in primary mediastinal large B-cell lymphoma: the emerging standard of care.
Vassilakopoulos TP; Pangalis GA; Katsigiannis A; Papageorgiou SG; Constantinou N; Terpos E; Zorbala A; Vrakidou E; Repoussis P; Poziopoulos C; Galani Z; Dimopoulou MN; Kokoris SI; Sachanas S; Kalpadakis C; Dimitriadou EM; Siakantaris MP; Kyrtsonis MC; Dervenoulas J; Dimopoulos MA; Meletis J; Roussou P; Panayiotidis P; Beris P; Angelopoulou MK
Oncologist; 2012; 17(2):239-49. PubMed ID: 22282906
[TBL] [Abstract][Full Text] [Related]
7. Thalidomide enhanced the efficacy of CHOP chemotherapy in the treatment of diffuse large B cell lymphoma: A phase II study.
Ji D; Li Q; Cao J; Guo Y; Lv F; Liu X; Wang B; Wang L; Luo Z; Chang J; Wu X; Hong X
Oncotarget; 2016 May; 7(22):33331-9. PubMed ID: 27129176
[TBL] [Abstract][Full Text] [Related]
8. Low absolute peripheral blood CD4+ T-cell count predicts poor prognosis in R-CHOP-treated patients with diffuse large B-cell lymphoma.
Kusano Y; Yokoyama M; Terui Y; Nishimura N; Mishima Y; Ueda K; Tsuyama N; Yamauchi H; Takahashi A; Inoue N; Takeuchi K; Hatake K
Blood Cancer J; 2017 Apr; 7(4):e558. PubMed ID: 28430176
[TBL] [Abstract][Full Text] [Related]
9. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma.
Dunleavy K; Pittaluga S; Maeda LS; Advani R; Chen CC; Hessler J; Steinberg SM; Grant C; Wright G; Varma G; Staudt LM; Jaffe ES; Wilson WH
N Engl J Med; 2013 Apr; 368(15):1408-16. PubMed ID: 23574119
[TBL] [Abstract][Full Text] [Related]
10. A comparison of pectoralis versus lumbar skeletal muscle indices for defining sarcopenia in diffuse large B-cell lymphoma - two are better than one.
Go SI; Park MJ; Song HN; Kim HG; Kang MH; Kang JH; Kim HR; Lee GW
Oncotarget; 2017 Jul; 8(29):47007-47019. PubMed ID: 28388585
[TBL] [Abstract][Full Text] [Related]
11. ABCG2 Q141K polymorphism is associated with chemotherapy-induced diarrhea in patients with diffuse large B-cell lymphoma who received frontline rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone chemotherapy.
Kim IS; Kim HG; Kim DC; Eom HS; Kong SY; Shin HJ; Hwang SH; Lee EY; Lee GW
Cancer Sci; 2008 Dec; 99(12):2496-501. PubMed ID: 19032367
[TBL] [Abstract][Full Text] [Related]
12. R-miniCHOP versus R-CHOP in elderly patients with diffuse large B-cell lymphoma: A propensity matched population-based study.
Al-Sarayfi D; Brink M; Chamuleau MED; Brouwer R; van Rijn RS; Issa D; Deenik W; Huls G; Mous R; Vermaat JSP; Diepstra A; Zijlstra JM; van Meerten T; Nijland M
Am J Hematol; 2024 Feb; 99(2):216-222. PubMed ID: 38014799
[TBL] [Abstract][Full Text] [Related]
13. Optimization of rituximab for the treatment of DLBCL (I): dose-dense rituximab in the DENSE-R-CHOP-14 trial of the DSHNHL.
Murawski N; Pfreundschuh M; Zeynalova S; Poeschel V; Hänel M; Held G; Schmitz N; Viardot A; Schmidt C; Hallek M; Witzens-Harig M; Trümper L; Rixecker T; Zwick C
Ann Oncol; 2014 Sep; 25(9):1800-1806. PubMed ID: 24928834
[TBL] [Abstract][Full Text] [Related]
14. Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL.
Martin P; Bartlett NL; Chavez JC; Reagan JL; Smith SM; LaCasce AS; Jones J; Drew J; Wu C; Mulvey E; Revuelta MV; Cerchietti L; Leonard JP
Blood; 2022 Feb; 139(8):1147-1159. PubMed ID: 34428285
[TBL] [Abstract][Full Text] [Related]
15. Intensified First Cycle of Rituximab Plus Eight Cycles of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone with Rituximab Chemotherapy for Advanced-Stage or Bulky Diffuse Large B-Cell Lymphoma: A Multicenter Phase II Consortium for Improving Survival of Lymphoma (CISL) Study.
Kim YR; Kim JS; Kim WS; Eom HS; Yang DH; Bae SH; Kim HJ; Lee JH; Oh SJ; Yoon SS; Kwak JY; Choi CW; Kim MK; Oh SY; Kang HJ; Nam SH; Shim H; Park JS; Mun YC; Suh C;
Cancer Res Treat; 2023 Oct; 55(4):1355-1362. PubMed ID: 36996864
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of combination therapy of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisolone for previously untreated diffuse large B-cell lymphoma in Japan.
Mizuoka T; Sakamaki H; Fuji S; Saito S; Murata T; Ohno S; Inubashiri N; Oshima T; Yamamoto K
J Med Econ; 2023; 26(1):1122-1133. PubMed ID: 37656225
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma.
Kambhampati S; Saumoy M; Schneider Y; Pak S; Budde LE; Mei MG; Siddiqi T; Popplewell LL; Wen YP; Zain J; Forman SJ; Kwak LW; Rosen ST; Danilov AV; Herrera AF; Thiruvengadam NR
Blood; 2022 Dec; 140(25):2697-2708. PubMed ID: 35700381
[TBL] [Abstract][Full Text] [Related]
18. Differential Efficacy From the Addition of Bortezomib to R-CHOP in Diffuse Large B-Cell Lymphoma According to the Molecular Subgroup in the REMoDL-B Study With a 5-Year Follow-Up.
Davies AJ; Barrans S; Stanton L; Caddy J; Wilding S; Saunders G; Mamot C; Novak U; McMillan A; Fields P; Collins GP; Stephens R; Cucco F; Sha C; van Hoppe M; Tooze R; Davies JR; Griffiths G; Schuh A; Burton C; Westhead DR; Du MQ; Johnson PWM
J Clin Oncol; 2023 May; 41(15):2718-2723. PubMed ID: 36972491
[No Abstract] [Full Text] [Related]
19. High rate of event-free survival at 24 months with everolimus/RCHOP for untreated diffuse large B-cell lymphoma: updated results from NCCTG N1085 (Alliance).
Witzig TE; LaPlant B; Habermann TM; McPhail E; Inwards DJ; Micallef IN; Colgan JP; Nowakowski GS; Ansell SM; Johnston PB
Blood Cancer J; 2017 Jun; 7(6):e576. PubMed ID: 28649983
[No Abstract] [Full Text] [Related]
20. Pembrolizumab With R-CHOP in Previously Untreated DLBCL: Sustained, High Efficacy, and Safety With Long-Term Follow-Up.
Ho C; Gopal AK; Till BG; Shadman M; Lynch RC; Cowan AJ; Wu QV; Voutsinas J; Rasmussen HA; Blue K; Ujjani CS; Cassaday RD; Fromm JR; Fang M; Smith SD
Clin Lymphoma Myeloma Leuk; 2024 Feb; 24(2):e33-e39.e1. PubMed ID: 37926672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
